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Background. Microalbuminuria is an important cardiovas-
cular risk factor, and appears to be a marker of early arterial
disease in patients with and without diabetes and/or hyperten-
sion. The aim of this study was to investigate prevalence of
albuminuria in hypertensive patients in clinical settings, as well
as to assess the efficacy of the angiotensin receptor blocker irbe-
sartan on the evolution of this risk marker in habitual clinical
practice.
Methods. KORAL-HT is a prospective, multicenter 1-year
follow-up study in inadequately controlled hypertensive pa-
tients. Demographic data, major cardiovascular risk factors, al-
buminuria, and clinical parameters were recorded at baseline
and at 6-month and 12-month visits. During the year of follow-
up, the patients received antihypertensive therapy with irbesar-
tan in addition to their usual antihypertensive regimen.
Results. A total of 1657 [802 diabetics (48.4%) and 855
nondiabetics (51.6%)] hypertensive patients were studied. The
prevalence of microalbuminuria in this sample was 62.5%. Af-
ter 1-year treatment with irbesartan, the percentage of pa-
tients with normoalbuminuria grew from 17.1% at baseline to
40.9% at 1-year follow-up. Blood pressure (BP) decreased from
157.3 ± 13.7/93.6 ± 9.2 mm Hg at baseline to 139.8 ± 13.12 mm
Hg and 136.1 ± 11.6/80.1 ± 8 mmHg at 6- and 12-month visits,
respectively. The percentage of patients who achieved BP tar-
gets increased progressively, 57.2% at 6 months, and 70.1% at
the study end.
Conclusion. This study shows that the population attending
Spanish HT centers have high prevalence of microalbuminuria.
The addition of irbesartan to the usual treatment in poorly con-
trolled hypertensive patients significantly improved BP control,
and reduced microalbuminuria both in diabetic and nondiabetic
patients. Our study confirms that similar results can be obtained
in normal clinical practice as in controlled clinical trials.
Cardiovascular diseases are the primary cause of death
and disability, and as such, require the development of
strategies for diagnosis, prevention, and treatment. Uri-
nary albumin excretion (UAE) in hypertensive patients
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is a continuous and progressive marker of renal dam-
age and cardiovascular events. This technique can be car-
ried out cheaply and easily [1, 2]. Target organ damage is
more frequent in patients with microalbuminuria [3], and
these patients have a higher rate of left ventricular mass
(LVM). High albumin/creatinine ratios correlated with
an increase of morbidity and mortality in hypertensive
patients and in patients with left ventricular hypertrophy
[4], as well. The relationship between microalbuminuria
and other risk factors has been widely demonstrated [5].
Microalbuminuria reflects vascular damage, and appears
to be a marker of early arterial disease. For this reason,
the assessment of urinary albumin excretion is an impor-
tant aspect for risk factor stratification in hypertensive
patients.
Blockade of the renin-angiotensin system (RAS) in-
hibits the vasoconstrictive effect of angiotensin II on the
renal efferent glomerular arteriole. The mesangial cell
proliferation induced by angiotensin II is also reduced.
This type of action has a highly significant renoprotective
effect, important in hypertensive patients, particularly in
diabetics [6–7].
The European Society of Hypertension and Cardiol-
ogy and the Seventh Report of the American Joint Na-
tional Committee guidelines recommend the monitoring
of urinary albumin excretion (UAE) and RAS interven-
tion in hypertensive patients and, even more strongly, en-
courage such monitoring and intervention when there is
evidence of renal damage, and in diabetic patients [8–9].
The PRIME study showed that irbesartan treatment
significantly modified the progression of renal damage
in hypertensive patients with type 2 diabetes mellitus
with microalbuminuria or proteinuria [10–11]. However,
there are insufficient data available on the prevalence
of albuminuria and the efficacy of RAS blockade in the
reduction of urinary albumin excretion in hypertensive
patients followed in clinical practice conditions. There-
fore, the objective of this study was to estimate the preva-
lence of microalbuminuria/albuminuria in poorly con-
trolled patients attending hypertensive units in Spain,
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and to evaluate the effect of 1 year’s treatment with irbe-
sartan on microalbuminuria/albuminuria in hypertensive
patients in conditions of clinical practice. The secondary
objectives were: (1) to evaluate the changes in systolic
and diastolic blood pressure (SBP and DBP) caused by
the irbesartan treatment; (2) to assess the percentage of
patients who achieve target blood pressure (BP); and (3)
to determine the effect of treatment with irbesartan on
the evolution of renal function.
DESIGN
KORAL-HT is an observational, prospective, 1-year
follow-up study in hypertensive, uncontrolled patients,
to whom irbesartan was added to their antihypertensive
treatment. Measurements were made at baseline and at
6- and 12-months’ follow-up. The protocol was approved
by the Clinical Research Ethics Committees.
METHODS
The study was carried out by 125 investigators from
105 hypertension units in Spain. A total of 1657 uncon-
trolled hypertensive patients (BP>140/90 mm Hg in non-
diabetics and BP >130/85 mm Hg in diabetic patients)
were studied and followed for 12 months. The patients
who had been treated with angiotensin-converting en-
zyme inhibitors or angiotensin II receptor antagonists
(ARBs) during at least the 2 weeks prior to inclusion
were excluded. Patients with secondary hypertension or
BP ≥ 210/110 mm Hg, unstable hypertension, type 1 di-
abetes, hyperkalemia >5.5 mEq/L, contraindications for
treatment with ARBs, or any serious concomitant dis-
ease which could affect follow-up were also excluded.
BP determination was carried out according to the WHO
guidelines [12]. Demographic data, major cardiovascular
risk factors, associated cardiovascular disease, albumin-
uria, and clinical parameters were all recorded. Patients’
visits were scheduled at the beginning, at 6 months, and
at the end of the study (12 months).
Routine biochemical and microalbuminuria tests were
performed by the laboratory of each center involved
in the study, following the usual practice of the center.
Based on the significance of the MICROHOPE study
[2], which established that any level of microalbuminuria
(A/Cr > 0.2 mg/mmol) directly correlates with cardiovas-
cular morbidity and mortality, the inclusion of patients
with microalbuminuria below 30 mg/day was permitted.
All patients determined to have microalbuminuria who
matched the inclusion criteria were admitted for a 1-year
follow-up treatment with irbesartan. Renal function was
evaluated with the Cockroft-Gault formula.
The irbesartan regimen dose was titrated from 150 mg
to 300 mg, and if target BP was not achieved, (BP < 140/90
mm Hg in nondiabetics, BP < 130/80 mm Hg in diabetics),
the following scheme of treatment was followed accord-
ing to the physician criteria: (1) irbesartan 300 mg + hy-
drochlorothiazide (HTZ) 12.5 mg; (2) irbesartan 300 mg
+ HTZ 12.5 mg + other antihypertensive drug other than
ARBs or ACEIs, until the patients reach the BP targets.
Statistical analysis
Data are expressed as mean ± SD. Microalbuminuria
levels are expressed as mean ± SE. Student t test was used
for baseline group comparisons, and Student paired t test
was used when comparing the variables before and after
intervention. Analysis of variance (ANOVA) was used
for comparisons for >2 groups. General linear model was
used to correct for confounding factors. Differences were
considered statistically significant at P < 0.05. All calcu-
lations were performed using the software SPSS 11.5 for
Windows (Chicago, IL, USA).
RESULTS
A total of 1657 patients were included in the study;
802 were diabetics (48.4%) and 855 were nondiabetics
(51.6%). Mean systolic and diastolic BP at the time of
inclusion was 157.7 ± 14.2 mm Hg and 93.3 ± 9.6 mm
Hg, respectively. Pulse pressure (PP) was 64.4 ± 13.9.
Seventy-six percent of the patients were receiving pre-
vious pharmacologic antihypertensive treatment, while
23.65% were not. The previous antihypertensive treat-
ment received was: calcium channel blockers (48%), di-
uretics (38.8%), beta-blockers (21.8%), alpha-blockers
(13.6%), and other hypertensive drugs (3.8%). Among
patients with previous hypertensive treatment, 79% were
on monotherapy, 17% were receiving 2 antihyperten-
sive drugs, 3.6% were receiving 3 drugs, and only 0.6%
was receiving 4 or more antihypertensive drugs. Thirty-
five percent of the patients were receiving lipid-lowering
agents, and 20.5% were on antiplatelet therapy. Among
diabetic patients, 70.6% were receiving either oral antidi-
abetic agents or insulin (78.6% of them were receiving
oral agents and 24.4% received insulin). Mean (±SD)
hemoglobin A1C of the diabetic patients was 6.9 (±1.4).
A percentage (17.1%) of the patients had an urinary
albumin excretion in the range of normoalbuminuria,
62.5% microalbuminuria, and in 20.4% of the patients,
the urinary albumin excretion was in the range of pro-
teinuria. The mean 24-hour urinary albumin excretion
rate was 317.8 mg/24 hours.
Table 1 shows demographic and clinical characteristics
of the diabetic and nondiabetic patients at the time of
inclusion in the study. Diabetic patients were older and
heavier. Mean diastolic BP was lower, and mean pulse
pressure higher in the diabetic patients. Ischemic heart
disease, cerebrovascular disease, and peripheral artery
disease were all significantly more prevalent among
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Table 1. Baseline characteristics of the diabetic and nondiabetic
patients
Nondiabetics Diabetics
N (Male/female) 855 (501/354) 802 (484/318)
Agea years (mean ± SD) 58.5 ± 12.7 62.3 ± 11
BMIa kg/m2 (mean ± SD) 28.7 ± 4.3 29.8 ± 4.6
SBP mm Hg (mean ± SD) 158 ± 14 157.4 ± 13
DBPa mm Hg (mean ± SD) 95.2 ± 10 91.2 ± 9
PPa mean ± SD 62.8 ± 13 66.1 ± 14
Target organ damage
Ischemic heart diseasea % 4.1 10.2
Cerebrovascular diseasea % 2.1 5.9
Peripheral artery diseasea % 2.8 8.4
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic blood pressure;
PP, pulse pressure.
aP < 0.001.
Table 2. Biochemical data of the diabetic and nondiabetic patients at
baseline (mean ± SD)
Nondiabetics Diabetics
Glucosea mg/dL 98.5 ± 14.5 156.8 ± 41.5
Creatinine mg/dL 1.1 ± 0.4 1.1 ± 0.3
Na mmol/L 140.4 ± 3.4 140.2 ± 3.9
K mmol/L 4.3 ± 0.4 4.5 ± 0.5
Uric acid mg/dL 6 ± 2.1 5.9 ± 1.6
Creatinine clearance mL/min 83.9 ± 34.5 79.7 ± 34.6
Total cholesterol mg/dL 217.6 ± 78.4 215.9 ± 41.5
LDL-C mg/dL 132.6 ± 35.8 131.6 ± 37.5
HDL-C mg/dL 51.5 ±14.1 50.5 ± 14.8
Triglyceridesa mg/dL 139.4 ± 82.2 165.8 ± 86.3
Albumin/creatinine ratioa mg/g 203.2 ± 114.7 328 ± 1725.9
24-h exc ratea mg/24h 276.2 ± 694.4 369.6 ± 686.9
Abbreviations are: Na, sodium; K, potassium; LDL-C, low-density lipoprotein
cholesterol; HDL-C, high-density lipoprotein cholesterol; 24-h exc rate, 24-hr
excretion rate.
aP < 0.001.
diabetic patients (P < 0.001). Table 2 shows comparison
of biochemical data at baseline between diabetic and non-
diabetic individuals. Fasting plasma glucose and triglyc-
eride concentrations were significantly higher in the
diabetic patients (P < 0.001). Additionally, urinary al-
bumin excretion (UAE) rate was significantly higher in
the diabetic group.
Of the 1657 patients who started the study, 1151 com-
pleted the treatment follow-up according to the planned
schedule. Given the conditions of normal clinical practice
under which the study was performed, a dropout rate
of about 30% was to be expected. The most common
reasons for study withdrawal were: lost to follow-up for
392 patients; investigator’s decision in 10 patients; lack
of compliance with protocol treatment or visit schedule
for 9 patients; consent withdrawal for 6 patients; adverse
reactions in 2 patients; and other reasons for 12 patients.
The reasons for withdrawal were unknown for 75 patients.
No significant differences (P < 0.01) were observed be-
tween the population that was included and that which
was followed through to the end of the study, except for
glycemia. Based on these results, we assumed that the
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Fig. 1. Urine albumin excretion at baseline, 6-month, and 12-month
visit in the diabetic and nondiabetic patients.
main characteristics of patients lost for the study follow-
up would not modify the results.
During the study, the patients were treated with a mean
dose of 250.7 ± 60.3 mg irbesartan. In the final visit,
76.3% of the patients were receiving treatment with 2 an-
tihypertensive drugs, 18.3% were receiving 3 drugs, and
4.6% were receiving 4 or more antihypertensive drugs.
Of the patients who received more than 1 drug, 29.4%
received diuretics, 20% beta-blockers, 51% CCB, 20%
alpha-blockers, and 2.9% other classes of drugs. In the
initial visit, 32.9% of the patients were receiving antidia-
betic treatment compared to the 15.3% at the final visit.
The percentage of patients treated with lipid-lowering
agents also fell from 33.5% in the initial visit to 20.6%
in the final visit. There were no significant changes in an-
tiplatelet therapy.
The effect of treatment on urine albumin excretion in
diabetic and nondiabetic groups during the study period
is shown in Figure 1. Mean 24-hour albumin excretion
rate decreased significantly at the 6-month and 12-month
follow-up measurements (P < 0.001). There was a signif-
icant and similar decrease in microalbuminuria in both
groups.
The percentage of patients with normo-, micro-, and
macroalbuminuria during the follow-up period is shown
in Figure 2. The proportion of patients with urine albu-
min excretion in the range of “normoalbuminuria” grew
significantly throughout the study, from 17.1% at the time
of inclusion to 40.9% after 1 year of treatment (Fig. 2).
BP evolution during the study follow-up
Both systolic and diastolic BP, and also pulse pressure
decreased significantly at the 6-month and 12-month vis-
its. Blood pressure (BP) decreased from 157.3 ± 13.7/
93.6 ± 9.2 mm Hg at baseline to 139.8 ± 13.1/82.6 ±
8.6 mm Hg and 136.1 ± 11.6/80.1 ± 8.1 mm Hg at 6-
and 12-month visits, respectively. At the 6-month study
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Fig. 2. Percentage of patients with macro-, micro-, and normoalbumin-
uria during the study period.
visit, 56.9% of the patients had achieved BP targets. Af-
ter the 1-year treatment with the study protocol, 70.1%
of the patients had achieved the study objective of BP. A
higher proportion of nondiabetic patients achieved the
BP target compared with diabetics (22%), but a lower
BP objective was established for the diabetic patients.
Evolution of renal function in patients treated with
irbesartan, based on the estimation of GFR using the
Cockcroft-Gault equation
The mean GFR decreased from 81.9 ± 34 mL/min at
baseline to 80.1 ± 31 mL/min at the end of the study (P <
0.01). However, when grouping the patients in diabetics
and nondiabetics, the reduction is still significant in non-
diabetic patients (83.9 ± 32 vs. 81.4 ± 30, P < 0.01), but
not in diabetic subjects (79.7 ± 37 vs. 79.8 ± 38).
There are other data worth mentioning, although not
included in the study objectives. There was a significant
reduction in fasting plasma glucose, which fell from a
mean value of 124.8 ± 42.4 at baseline to 119.3 ± 35.4
after 1 year of treatment (P < 0.001). The reduction
was more pronounced in the diabetic group. In addition,
there was a reduction in total cholesterol (218.1 ± 71.3 vs.
203.3 ± 30.2, P < 0.001), LDL cholesterol (132.5 ± 36.9
vs. 122.0 ± 29.5, P < 0.001), and triglycerides (151.1 ±
81.8 vs. 143.4 ± 63.8, P < 0.001). The reduction was more
pronounced in the group of diabetic patients.
DISCUSSION
This study shows high urinary albumin excretion that
was reduced by reaching BP targets with the addition
of the ARB irbesartan in uncontrolled hypertensive pa-
tients attending hypertension units in Spain.
The objective of hypertension treatment includes the
reduction of cardiovascular and cerebrovascular morbid-
ity and mortality, and also, the reduction of the pro-
gression of renal insufficiency. Many studies in different
populations have shown microalbuminuria to be an
important risk factor of cardiovascular morbidity and
mortality, both in diabetic and nondiabetic patients.
Determination of microalbuminuria should be a routine
practice because its appearance, progression to protein-
uria, or regression to normoalbuminuria are correlated
with a higher or lower risk of coronary heart disease,
stroke, or peripheral vascular disease. In other words, uri-
nary albumin excretion is a marker of cardiovascular risk,
and also a marker of treatment efficacy.
In the present study, we examined the prevalence of
microalbuminuria in a sample of consecutive patients at-
tending to the hypertension units of 15 hospitals included
in the KORAL-HT study group, distributed throughout
the country. In this nonselected sample of hypertensive
patients, the prevalence of microalbuminuria was over
60%, much higher than the prevalence of 43% described
in Spanish diabetics participating in the DEMAND study,
and also higher than the 18% described in hypertensive
patients attending primary care clinics in our country [13]
and than the 11% for patients in the EPIC-Norfolk study
[14]. This prevalence shows that patients seen in the hy-
pertension units of the KORAL-HT study have a consid-
erably higher cardiovascular risk. The higher prevalence
of patients with microalbuminuria in our study can be ac-
counted for by the higher presence of cardiovascular risk
factors and target organ damage of our patient popula-
tion, attended at specialized hospital-based hypertension
units.
The patients included in the 1-year follow-up study
(KORAL-HT) consisted mainly of an urban population,
mean age 60.3 years, of which 48.4% were diabetics. The
patients’ age and risk factors imply a very high risk. Only
23.6% of the patients were not receiving antihyperten-
sive treatment before their inclusion in the study. In gen-
eral, diabetic patients were older, with a higher BMI and
a higher prevalence of associated CV disease. The intro-
duction and titration of irbesartan (150 mg to 300 to 300 +
HCTZ) achieved a significant reduction in blood pressure
throughout the follow-up period. A reduction of 22 mm
Hg in SBP and 13.2 mm Hg in DBP was achieved com-
pared to the baseline. The drop in blood pressure was
maintained over the follow-up. The percentage of con-
trolled patients was 56% at 6 months and 70% at the end
of the study. The reduction in BP was remarkable, tak-
ing into account that most patients were already receiving
other antihypertensive drugs. Mean blood pressure at the
end of the study suggests that blood pressure control in
clinical practice of patients with a high CV risk and/or dia-
betes can be similar to that obtained in controlled clinical
trials [7, 10–11, 15]. The percentage of diabetic patients
that achieved the blood pressure objective was less than
in nondiabetics, reflecting a lower response to antihyper-
tensive treatment in diabetics, which has also been seen
in other studies.
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Systemic BP reduction, and even more strongly, intra-
glomerular pressure drop, has been shown to effectively
decrease the urinary albumin excretion rate. The present
study was aimed at demonstrating the efficacy of irbe-
sartan treatment to reduce microalbuminuria in uncon-
trolled hypertensive diabetics and nondiabetics in routine
clinical practice.
Parallel to the significant blood pressure decrease, a
remarkable reduction in the urinary albumin excretion
rate was also observed. The proportion of patients with
normoalbuminuria increased from 17.1% at baseline to
40.9% at the end of the study, while the percentage of
patients with microalbuminuria dropped from 62.5% at
baseline to 48.3% at the study end, and that of clinical
proteinuria dropped from 20.4% at baseline to 10.7%
at the end. Microalbuminuria decreased during the 12-
month follow-up in spite of the absence of significant
blood pressure changes in the last semester. There was
a progressive reduction in microalbuminuria. At the end
of the study, a global reduction in urinary albumin ex-
cretion rate greater than 60% was achieved compared to
baseline, mimicking IRMA 2 study results.
Renal function was maintained rather stable over the
study period (81.9 ± 34.1 baseline vs. 80.2 ± 31.6 P <
0.01 at study end). The reduction of GFR, minimal, was
only significant in nondiabetic patients, and probably sec-
ondary to functional factors (reduction of BP and intra-
glomerular pressure induced by irbesartan treatment).
During the study there was an improvement in lipid pa-
rameters: reduction in total cholesterol and triglycerides
with a significant rise in HDL cholesterol. Although our
objectives did not encompass treatment and control of hy-
perlipidemia, investigators’ intervention to correct lipid
abnormalities was likely, albeit no changes in cholesterol
lowering drug therapy were recorded. Besides, a possible
beneficial effect of the renin-angiotensin system blockade
on carbohydrate metabolism cannot be ruled out [17, 18].
CONCLUSION
High doses of irbesartan can reduce and even normal-
ize microalbuminuria both in diabetic and nondiabetic
patients.
The benefits achieved in BP control and microalbu-
minuria reproduce in the clinical practice the results ob-
tained in controlled trials. The positive evolution of lipid
and metabolic parameters support the benefits of obser-
vational studies, beyond the study primary end point.
ACKNOWLEDGMENTS
The authors would like to thank the hypertension units’ physicians
who participated as investigators and who made the KORAL HTA
study possible. This study was supported by a grant from Bristol-Myers
Squibb Spain, Madrid.
APPENDIX
Clinical investigators of the KORAL-HT study who pro-
vided and cared for study patients
Luis Miguel Lou Arnal, Ricardo Go´mez Sa´nchez, Vicente Barrio Lu-
cia, Francisco Martı´nez Deben, Michel Jaquet Herter, Alfonso Otero
Gonza´lez, Ignacio Vazquez de Prada Gonza´lez, Ramo´n Pacheco Sara-
bia, Francisco Gil, MaJose´ Aladre´n Regidor, Pedro Vives Ague´da, Julio
Herrera Pe´rez de Villar, Francisco Ferna´ndez Vega, Salvador Tranche
Iparraguirre, Joaquin Aracil Villar, Miguel A´ngel Prieto Dı´az, Ramo´n
Delgado Lillo, Jose´ Enrique Lo´pez Paz, Ma Jesu´s Domı´nguez San-
tana, Jesu´s Honorato, Francisco Martı´n Marı´n, Jesu´s Cebollada Muro,
Najaty Suliman Jabary, Jose´ Bueno Go´mez, Jose´ Vicente Lozano Vi-
dal, Antonio Robles Iniesta, Pedro Escriche Roberto, Carmen Caro
Narrillos, Jose Ma Martı´nez Garcı´a, Emilio Marque´s Contreras, Jose
Antonio Madrigal Vilata, Fco Javier Martı´nez Martı´n, Jose´ Carlos
Rodrı´guez Pe´rez, Saturnino Sua´rez Ortega, Jose´ Luis Gorriz Teruel,
Jaume Planas, Francisco Javier del Cazo, Marc Cuixart Pe´rez, Josep
Soler Amigo´, Andre´s de la Pen˜a Ferna´ndez, Javier Tisaire Sa´nchez,
Santos Casado Pe´rez, Juan Oco´n Pujadas, Isabel Martı´nez Ferna´ndez,
Agustı´n Minguez Sanz, Pedro Aranda Lara, Ana Ma Tormo Cantos,
Alfonso Pe´rez Garcı´a, Ma Jose´ Ferna´ndez-Rojes Luis, Rosa Sa´nchez
Herna´ndez, Carmen Mon, Jacinto Ferna´ndez Pardo, C. Pintor, Emilio
Lo´pez-Vidriero Abello´, Fco. Javier Rodrı´guez, Juan Antonio Diviso´n
Garrote, Luis Miguel Artigao Roenas, Ma Eugenia Plagaro, Jose´ Javier
Torrijos Gil, Jordi Calls Ginesta, Jose´ Ma Pascual, Pedro Cardona
Ausina, Beatriz Acebro´n Sa´nchez-Fortu´n, Juan Carlos Romero Pe´rez,
Gabriel Pou Serradell, Carmen Rosa Gonza´lez Ferna´ndez, Carlota
Garcı´a Arias, Antonio Grilo Reina, Luis Miguel Ruilope, Antonio
Lie´bana Can˜ivol, Josep Redon Ros, Blas Gil Extremera, Emilio Oli-
vas Garcı´a, Pedro Cipriano Gordo Fraile, Javier Vivanco Martı´nez,
Ibrahim Aziz Basha, Da´maso Escribano Sevillano, Josep Marı´a Gal-
cera´n Gui, Ramo´n Gonza´lez, Javier Sobrino Martı´nez, Cesar Gonza´lez
Martı´nez, Ma Concepcio´n Laviades A´lvarez, Rafael Virto Ruiz, Manuel
A´ngel Rodrı´guez Martı´nez, Fernando de A´lvaro, Vicente Valor Font,
Juanjo Villarreal Balza, Aquilino Sa´nchez Purificacio´n, Ma del Mar
Biechi Baldan, Francisco Ferna´ndez Montero, Joaquı´n Franco Ce-
bria´n, Jose Latorre Herna´ndez, Pilar Rosique Delmas, Pablo Go´mez
Ferna´ndez, Josep Bromsons, Jose´ Ramo´n Calabuig Alborch, Alberto
Sanjua´n Herna´ndez, Lorenzo Pastor Mouro´n, Manuel Lo´pez Jime´nez,
Adnan Hawari Meilud, Jesu´s Martı´n Garcı´a, Joseph Esque Panavera,
Carmen Sua´rez Ferna´ndez, Da´maso Sanz Guajardo, Diego Biedma
A´lvarez, Jose´ Luis Bianchi Llave, Francisco Pe´rez Corral, Jose´ Saba´n
Ruiz, Gonzalo de la Lama Leo´n, Antoni Pellegri, Fco. Javier Guere-
diaga Madariaga, Julio Cesar Bla´zquez Encinar, Javier Solı´s Villa, Ma
Cristina Ligorria Berguio, Benito Maceira Cruz, Rosario Garcı´a Pala-
cios, Esther Salces Sa´ez, Manuel Luque Otero, Melchor Rodrı´guez Gas-
par, Jesu´s Grande Villoria, Fernando Tornero Molina, A´ngel Sa´nchez
Rodrı´guez, Celia Ferna´ndez-Torres, Jose Luı´s Ası´n Marcotequi, Juan
Jose´ Unzue Gaztelu, Gregorio Tiberio Lo´pez.
Reprint requests to Fernando de A´lvaro, Servicio de Nefrologı´a, Hos-
pital Universitario La Paz, Madrid, Spain.
E-mail: fdealvaro@infonegocio.com
REFERENCES
1. RITZ E: Albuminuria and vascular damage: The vicious twins. N
Engl J Med 348:2349–2352, 2003
2. GERSTEIN HC, MANN JFE, YI Q, et al: Albuminuria and risk of car-
diovascular events, death, and heart failure in diabetic and non di-
abetic individuals. JAMA 286:421–426, 2001
3. JENSEN JS, FELDT-RASMUSSEN B, BORCH-JOHNSEN K, et al: Microalbu-
minuria and its relation to cardiovascular disease and risk factors.
A population-based study of 1254 hypertensive individuals. J Hum
Hypertens 11:727–732, 1997
4. WACHTELL K, IBSEN H, OLSEN MH, et al: Albuminuria and cardiovas-
cular risk in hypertensive patients with left ventricular hypertrophy:
The LIFE study. Ann Intern Med 139:901, 2003
5. BRAZILAY JI, PETERSON D, CUSHMAN M, et al: The relationship of
cardiovascular risk factors to microalbuminuria in older adults with
S-34 A´lvaro et al: Microalbuminuria in hypertensive patients
or without diabetes mellitus or hypertension: The cardiovascular
health study. Am J Kidney Dis 44:25–34, 2004
6. RAIJ L: Recommendations for the management of special popula-
tions: Renal diseases in diabetes. Am J Hypertens 16:46S–49S, 2003
7. BRENNER BM, COOPER ME, DE ZEEUW D, et al: Effects of losartan on
renal and cardiovascular outcomes in patients with type 2 diabetes
and nephropathy. N Engl J Med 345:861–869, 2001
8. CHOBANIAN AV, BAKRIS GL, BLACK HR, et al: The Seventh Report of
the Joint National Committee on prevention, detection, evaluation
and treatment of high blood pressure. JAMA 289:2560–2572, 2003
9. GUIDELINES COMMITTEE: 2003 European Society of Hypertension-
European Society of Cardiology guidelines for the management of
arterial hypertension. J Hypertens 21:1011–1053, 2003
10. PARVING HH, LEHNER H, BRO¨CHNER-MORTENSEN J, et al: The effect of
irbesartan on the development of diabetic nephropathy in patients
with type 2 diabetes. N Engl J Med 345:870–878, 2001
11. LEWIS EJ, HUSICKER LG, CLARKE WR, et al: Renoprotective effect
of the angiotensin-receptor antagonist irbesartan in patients with
nephropathy due to type 2 diabetes. N Engl J Med 345:851–860,
2001
12. 1999 World Health Organization International Society of Hyperten-
sion Guidelines for the management of Hypertension. J Hypertens
17:151–183, 1999
13. AGUIRRE B: Prevalence of microalbuminuria in a hypertensive pop-
ulation of northern Navarra and its relation to other cardiovascular
risk factors. Anales Sistema Sanitario de Navarra 27:27–36, 2004
14. BOEKHOLDT SM, PETERS RJ, HACK CE, et al: IL-8 plasma concen-
trations and the risk of future coronary artery disease in apparently
healthy men and women. The EPIC-Norfolk Prospective Popula-
tion Study. Arterioscler Thromb Vasc Biol 24:1503–1508, 2004
15. HANSSON L, ZANCHETTI A, CARRUTHERS SG, et al: Effects of inten-
sive blood-pressure lowering and low-dose aspirin in patients with
hypertension: Principal results of the Hypertension Optimal Treat-
ment (HOT) randomised trial. HOT Study Group. Lancet 351:1755–
1762, 1998
16. ANDERSEN S, BROCHNER-MORTENSEN J, PARVING HH: Kidney func-
tion during and after withdrawal of long-term irbesartan treatment
in patients with type 2 diabetes and microalbuminuria. Irbesartan in
Patients With Type 2 Diabetes and Microalbuminuria Study Group.
Diabetes Care 26:3296–302, 2003
17. LINDHOLM LH, IBSEN H, DAHLO¨F B, et al: Cardiovascular morbid-
ity and mortality in patients with diabetes in the Losartan Inter-
vention For Endpoint reduction in hypertension study (LIFE): A
randomised trial against atenolol. Lancet 359:1004–1010, 2002
18. JULIUS S, KJELDSEN SE, WEBER M, et al: Outcomes in hypertensive
patients at high cardiovascular risk treated with regimens based
on valsartan or amlodipine: The VALUE randomised trial. Lancet
363:2022–2031, 2004
